Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Locally Recurrent Breast Cancer”

42 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 42 results

Large-scale testing (Phase 3)Looking for participantsNCT06081959
What this trial is testing

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 376
Large-scale testing (Phase 3)Study completedNCT02163694
What this trial is testing

Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AbbVie 513
Testing effectiveness (Phase 2)Study completedNCT00559507
What this trial is testing

Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery

Who this might be right for
Estrogen Receptor-negative Breast CancerMale Breast CancerProgesterone Receptor-negative Breast Cancer+4 more
National Cancer Institute (NCI) 12
Testing effectiveness (Phase 2)Study completedNCT02614794
What this trial is testing

Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Seagen Inc. 612
Testing effectiveness (Phase 2)Active Not RecruitingNCT06172127
What this trial is testing

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
MedSIR 165
Testing effectiveness (Phase 2)Ended earlyNCT01912963
What this trial is testing

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMetastatic Breast Cancer
Dana-Farber Cancer Institute 32
Not applicableActive Not RecruitingNCT07018427
What this trial is testing

Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Who this might be right for
Breast NeoplasmsTriple Negative Breast CancerHR+, HER2-, Advanced Breast Cancer+1 more
Peking University Cancer Hospital & Institute 70
Early research (Phase 1)Looking for participantsNCT05098210
What this trial is testing

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous Melanoma+22 more
Fred Hutchinson Cancer Center 28
Testing effectiveness (Phase 2)Study completedNCT03383679
What this trial is testing

Study on Androgen Receptor and Triple Negative Breast Cancer

Who this might be right for
Breast Cancer FemaleTriple Negative and Androgen Receptor Positive
UNICANCER 94
Early research (Phase 1)Ended earlyNCT03878524
What this trial is testing

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAnatomic Stage IV Breast Cancer AJCC v8Anemia+47 more
OHSU Knight Cancer Institute 2
Large-scale testing (Phase 3)Study completedNCT00006459
What this trial is testing

Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company
Large-scale testing (Phase 3)Study completedNCT00703326
What this trial is testing

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company 1,144
Large-scale testing (Phase 3)Active Not RecruitingNCT07386938
What this trial is testing

The Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer

Who this might be right for
Locally Advanced Breast CancerMetastatic Breast Cancer
R-Pharm 246
Testing effectiveness (Phase 2)UnknownNCT00006120
What this trial is testing

Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
GERCOR - Multidisciplinary Oncology Cooperative Group
Large-scale testing (Phase 3)Active Not RecruitingNCT05347134
What this trial is testing

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 254
Large-scale testing (Phase 3)Ended earlyNCT02054338
What this trial is testing

Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Pierre Fabre Medicament 1,004
Large-scale testing (Phase 3)Looking for participantsNCT06841354
What this trial is testing

Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Who this might be right for
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC 1,000
Testing effectiveness (Phase 2)Study completedNCT01427933
What this trial is testing

Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company 141
Early research (Phase 1)Active Not RecruitingNCT01351909
What this trial is testing

Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Locally Advanced Unresectable Breast CarcinomaMetastatic Breast CarcinomaRecurrent Breast Carcinoma+3 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Study completedNCT00696072
What this trial is testing

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Who this might be right for
Metastatic Breast Cancer
Bristol-Myers Squibb 120
Next Page